NCT02114385已完成3 期
A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 500
- 试验地点
- 7
- 主要终点
- Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18
研究概览
简要总结
Primary objective
To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
详细描述
Secondary objectives
- To evaluate the tolerability of V503 in 16- to 26-year-old men.
- To summarise humoral immune responses, including anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 GMTs and seroconversion rates at 4 weeks post-dose 3, in 16- to 26-year-old men who received V503 or GARDASIL
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 16 Years 至 26 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject is a man, between the ages of 16 years and 0 days and 26 years and 364 days on the day of enrolment.
- •Subject is a man who has had no more than 5 lifetime female sexual partners.
- •Subject is judged to be in good physical health on the basis of medical history, physical examination, and laboratory results.
- •Subject, or subject's parent or guardian, fully understand study procedures, alternative treatments available, the risks involved with the study, and voluntarily agree to participate by giving written informed consent.
排除标准
- •Subject who has had sex with a male partner.
- •Subject has a history of HPV-related external genital lesions or HPV-related anal lesions
- •Subject has a known allergy to any vaccine component, including aluminium, yeast, or BENZONASE
- •Subject has a history of severe allergic reaction that required medical intervention.
- •Subject has thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
- •Subject is concurrently enrolled in clinical studies of investigational medicinal products.
- •Subject has donated blood within 1 week prior to the Day 1 vaccination, or intends to donate during Day 1 through Month 7 of the study.
- •Subject is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
- •Subject has had a splenectomy.
- •Subject is receiving or has received in the year prior to enrolment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide, TNF-α antagonists, monoclonal antibody therapies, intravenous gamma globulin, antilymphocyte sera, or other therapy known to interfere with the immune response.
- •Subject has received any immune globulin product or blood-derived product within the 6 months prior to the Day 1 vaccination, or plans to receive any such product during Day 1 through Month 7 of the study.
- •Subject has received non-replicating (inactivated) vaccines within 14 days prior to the Day 1 vaccination or has received replicating (live) vaccines within 21 days prior to the Day 1 vaccination.
- •Subject has received a marketed HPV vaccine, or has participated in an HPV vaccine clinical trial and has received either active agent or placebo.
- •Subject has had a fever within the 24-hour period prior to the Day 1 vaccination.
- •Subject has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
- •Subject is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
- •Subject is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
- •Subject, or subject's parent or guardian, is or has an immediate family member (spouse or children) who is investigational site or sponsor staff directly involved with this trial.
研究组 & 干预措施
V503
Experimental
9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
干预措施: V503 (Biological)
GARDASIL
Active Comparator
Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
干预措施: GARDASIL (Biological)
结局指标
主要结局
Geometric Mean Titers (GMTs) to HPV Types 6/11/16/18
时间窗: 4 weeks postdose 3 (Month 7)
Serum antibodies to HPV types 6, 11, 16, and 18 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL.
次要结局
- GMTs to HPV Types 31/33/45/52/58(4 weeks postdose 3 (Month 7))
- Percentage of Participants Who Are Seropositive for HPV Types 6/11/16/18/31/33/45/52/58(4 weeks postdose 3 (Month 7))
- Percentage of Participants With Study Discontinuation Due to an Adverse Event(Up to Month 7)
- Percentage of Participants With Maximum Temperature ≥37.8 °C(Up to 5 days after any vaccination)
- Percentage of Participants With One or More Serious Adverse Events(Up to 15 days after any vaccination)
- Percentage of Participants With One or More Adverse Events(Up to 15 days after any vaccination)
- Percentage of Participants With One or More Injection-site Adverse Reactions(Up to 5 days after any vaccination)
- Percentage of Participants With One or More Systemic Adverse Events(Up to 15 days after any vaccination)
研究者
研究点 (7)
Loading locations...
相似试验
已完成
3 期
Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)Human PapillomavirusNCT01304498Merck Sharp & Dohme LLC600
已完成
2 期
Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of AsthmaAsthmaNCT01472757Vectura Limited374
终止
2 期
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes InfectionGenital HerpesHSV-2 InfectionNCT03146403Genocea Biosciences, Inc.33
已完成
3 期
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)Genital WartsCervical CancerVaginal CancerVulvar CancerHuman Papillomavirus InfectionNCT00543543Merck Sharp & Dohme LLC14,840
招募中
4 期
An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's DiseaseAlzheimer's DiseaseNCT05908695Green Valley (Shanghai) Pharmaceuticals Co., Ltd.1,312